Beacon NewsFlashes – July 25, 2011

J&J Announces Shortage Of Doxil – Johnson & Johnson announced manufacturing delays last week that will result in a temporary shortage of Doxil (doxorubicin liposomal), which is approved in combination with Velcade (bortezomib) for previously treated multiple myeloma patients. The company is estimating that shipments of Doxil will resume in late August and asked physicians not to start any new patients on Doxil until then. Last month, the company informed doctors about the potential shortage so physicians could discuss treatment options with their patients who might be affected by the shortage. For more information, see the Johnson & Johnson announcement about the shortage. Updates on the situation will be available on the Doxil website.
Children Raise $8.4 Million In Spare Change To Support LLS – Students across the United States recently raised $8.4 million for the Leukemia & Lymphoma Society (LLS) to fund research for blood cancers, including multiple myeloma, as well as provide services and support for blood cancer patients. The students put collection jars in their classrooms and collected spare change over a three-week period during this past school year. The top fundraising class at each school received a pasta party from Olive Garden. Over the past 17 years, this program has raised more than $61 million for the LLS. For more information, see the Olive Garden press release.
Multiple Myeloma Educational Program – An educational program for multiple myeloma patients will be held on August 6 in Richmond, VA. A physician specializing in multiple myeloma will talk about treatment options for myeloma patients as well as answer attendee’s questions. A multiple myeloma patient will also speak about his experiences. Registration will begin at 9:30 a.m., and the program will start at 10 a.m. at the Westin Richmond. The event is sponsored by Millennium, the manufacturer of Velcade. For more information, see the Beacon event description or call 1-866-508-6181.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
Related Articles:
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- ASCO 2018 Update – Expert Perspectives On The Key Multiple Myeloma-Related Oral Presentations
- bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)
- Could A Decades-Old Antibiotic Have Anti-Myeloma Activity?